Navigating challenges in HPAPI development and manufacturing

Webinar On Demand

High potency active pharmaceutical ingredients (HPAPIs) account for over 50% of today’s small molecule new chemical entity (NCE) drug pipeline. Although they represent a revolutionary pharmaceutical advancement in the areas of oncology treatments and personalized medicine, their development and manufacturing carry inherent risks due to their toxicity levels.

This webinar covers key considerations in developing and manufacturing HPAPIs, including product containment strategies, personnel protection needs, and cross-contamination risks.

Specific webinar key takeaways include:

  • The remarkable growth of HPAPIs in the new chemical entity small molecule drug pipeline
  • Unique considerations and challenges involved in developing and manufacturing HPAPIs
  • The role of product containment, personnel protection, and cross-contamination management
  • Insights into specialized facilities and state-of-the-art equipment for handling HPAPIs
  • The overall necessity of robust cleaning procedures and verification process requirements

Additionally, viewers will explore how an experienced CDMO partner like Thermo Fisher Scientific can help provide the right knowledge, infrastructure, and commitment to safety that’s needed to help biopharma companies overcome various industry challenges related to HPAPI development and manufacturing.

Watch the on-demand webinar to learn more.